Carcinosarcoma of the breast with massive osseous malignant component: a basal-like entity with myoepithelial differentiation

Open access


We present the case of a 77 year old patient with a primary breast carcinosarcoma composed mostly of an osteogenic sarcoma of fibroblastic type in which only immunohistochemical analysis disclosed the presence of a minor malignant epithelial component. The malignant mesenchymal component derives from dedifferentiation of myoepithelial cells since myoepithelial markers are positive. Also, like the majority of the other metaplastic carcinomas in the breast, carcinosarcoma is a basal type of tumor that will not respond to endocrine drugs or Her2/neu therapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Moinfar F.: Essentials of diagnostic breast pathologya practical approach. Springer; 2007: 234-236

  • 2. Ninomiya J Oyama T Horiguchi J Koibuchi Y Yoshida T Iijima K et al: Two cases of breast cancer with cartilaginous and osseous metaplasia. Breast Cancer. 2005;12(1):52-6.

  • 3. Kijima Y Umekita Y Yoshinaka H Owaki T Sakamoto A Yoshida H et al: A case of breast carcinoma with cartilaginous and osseous metaplasia. Breast Cancer. 2006;13(2):214-9.

  • 4. Rosen PP.: Rosen’s breast pathology. 2nd ed. Philadelphia PA: Lippincott- Williams&Wilkins; 2001: 425-452

  • 5. Tavassoli FA Devilee P.: Tumours of the breast and female genital organs. Lyon France IARC Press; 2003: p 37-41

  • 6. Tavassoli Fattaneh: Pathology of the breast. Hong- Kong McGraw-Hill Professional 1999: p 504

  • 7. An T. Grathwohl M. Frabe W.J.: Breat carcinoma with osseous metaplasia: An electron microscopic study. Am.J.Clin.Pathol. 1984 81: 127-132

  • 8. Chhieng C Cranor M Lesser ME Rosen PP.: Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol. 1998 Feb;22(2):188-94.

  • 9. Tavassoli Fattaneh: Pathology of the breast. Hong- Kong McGraw-Hill Professional 1999: p 614

  • 10. Carter MR Hornick JL Lester S Fletcher CD.: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006 Mar;30(3):300-9.

  • 11. Rungta S Kleer CG.: Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights. Arch Pathol Lab Med. 2012 Aug;136(8):896-900

  • 12. Bae SY Lee SK Koo MY Hur SM Choi MY Cho DH et al: The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011 Apr;126(2):471-8

  • 13. Davis WG Hennessy B Babiera G Hunt K Valero V Buchholz TA et al: Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005 Nov;29(11):1456-63.

  • 14. Gibson G.R. Qian D. Ku J.K. et al. Metaplastic breast cancer: clinical features and outcomes Am. Surg. 71 (2005) 725-730

  • 15. .Weigelt B Kreike B Reis-Filho JS.: Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009 Sep;117(2):273-80. Epub 2008 Sep 25.

  • 16. Gutman H Poouck RE Janjan NA et al: Biologic distinction and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg. 1995; 180: 193-199

  • 17. Tseng WH Martinez SR.: Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011 Jan;18(1):94-103

  • 18. Liedtke C Mazouni C Hess KR André F Tordai A Mejia JA et al: Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81

  • 19. Leibl S. Moinfar F.: Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J.Clin.Pathol. 2005; 58: 700-704

Journal information
Impact Factor

IMPACT FACTOR 2018: 0.800
5-year IMPACT FACTOR: 0.655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 159 90 2
PDF Downloads 72 46 1